Treatment Considerations in Older Adult Oncology
As the population ages, treatment considerations in older adult patients with cancer become relevant for all specialties. Proper selection of patients is the key to administering effective and safe cancer treatment, including knowing which patients should receive supportive care earlier.
Category
  • Senior Adult Oncology
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Immune Checkpoint Inhibitor Toxicities
Practical knowledge and skills are required to manage the needs of the growing patient population treated with ICIs, particularly as our understanding of best practices for addressing complex toxicities evolves.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
The Role of Biosimilars in Cancer Treatment
Challenges remain in the acceptance of biosimilars by physicians, payers and patients in the U.S., similar to those faced by generic drugs when they were first introduced to the market. Increased education and awareness of the FDA-approval process for biosimilars and increased understanding of the evidence required to demonstrate their safety and efficacy will help to close this practice gap and ensure the acceptance and use of biosimilars in clinical practice.
Category
  • Biosimilars
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
The Role of Integrative Medicine in Cancer
Clinician education on the topic of integrative therapies can help patients be informed enough to make the best decisions regarding non-conventional and conventional therapies to optimize their oncologic outcomes and quality of life.
Category
  • Supportive Care Topics
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers
There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.
Category
  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers.
Category
  • Genetic/Familial High-Risk Assessment
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Metastatic Breast Cancer
The decision-making process for metastatic breast cancer involves a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies. With expanding treatment options, clinicians need to understand important criteria used in picking optimal first-and subsequent line therapies for individuals with metastatic breast cancer and also have a knowledge of the biomarkers that should be tested to guide therapeutic decisions in patients with metastatic breast cancer. 
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Role of Biomarkers in Individualizing Treatment Selection for Patients with Cancer
Biomarker testing is increasingly being utilized to match patients with appropriate therapies.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Gliomas: Individualized Treatment Options
Histopathologic and molecular characterization of gliomas should now be standard practice, as specific markers used to define molecular subgroups among some gliomas have been shown to have prognostic value.
Category
  • Central Nervous System Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia
Advances in the molecular understanding of acute myeloid leukemia (AML) has enhanced risk stratification and optimized therapeutic strategies. However, there is still a need for improved therapeutic strategies to combat AML disease progression, especially in older patients. Informing clinicians about therapeutic advances and necessary supportive care precautions will aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages